Mangalam Drugs & Organics Quarterly Results for Trading Insights
In Mar 2026, Mangalam Drugs & Organics (MANGALAM) reported revenue ₹67 Cr and net profit ₹-13 Cr — revenue -8.2% YoY. For annual financials, live price and key ratios, visit Mangalam Drugs & Organics share price screener.
MANGALAM Quarterly Results — Revenue, Profit & EPS Highlights
Mangalam Drugs & Organics latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore MANGALAM price trends to track price trends across different timeframes.
- Revenue of ₹67 Cr in Mar 2026 (+36.7% vs Sept 2025, -8.2% vs Mar 2025)
- Net Profit of ₹-13 Cr in Mar 2026 (-85.7% vs Sept 2025)
- EBITDA of ₹-6 Cr in Mar 2026 (-100.0% vs Sept 2025)
- Operating Margin of -8.0% in Mar 2026 (-2.0pp vs Sept 2025)
- Earnings Per Share of ₹-8.48 in Mar 2026 (-82.8% vs Sept 2025)
Mangalam Drugs & Organics Quarterly Results — Revenue, EBITDA, Net Profit & EPS
MANGALAM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 67 | 49 | 73 | 57 | 59 | 36.7% | -8.2% |
| Net Profit (₹ Cr) | -13 | -7 | 0 | -14 | -10 | - | - |
| EBITDA (₹ Cr) | -6 | -3 | 10 | -5 | -1 | - | - |
| EPS (₹) | -8.48 | -4.64 | 0.04 | -8.72 | -6.21 | - | - |
| Operating Margin (%) | -8.0% | -6.0% | 14.0% | -8.0% | -3.0% | - | - |
MANGALAM Share Price Trend — 1-Year Movement Across Quarterly Results
Mangalam Drugs & Organics 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with MANGALAM fair value to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
MANGALAM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Mangalam Drugs & Organics latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores